Sun Pharmaceutical Sees Significant Open Interest Surge Amid Mixed Market Signals

Open Interest and Volume Dynamics

On 24 March 2026, Sun Pharma's open interest (OI) in derivatives rose sharply to 1,28,548 contracts from 1,13,387 the previous day, an increase of 15,161 contracts or 13.37%. This expansion in OI was accompanied by a futures volume of 85,090 contracts, underscoring robust trading activity. The futures segment alone accounted for a notional value of approximately ₹1,79,212 lakhs, while options contracts contributed an overwhelming ₹35,118 crore in value, culminating in a total derivatives turnover of ₹1,81,889 lakhs.

The underlying stock price stood at ₹1,765, reflecting a slight decline of 0.38% on the day, underperforming the Pharmaceuticals & Biotechnology sector which gained 1.03%, and the Sensex which rose 1.77%. This divergence between derivatives activity and spot price movement suggests that market participants may be positioning for a directional move that is not yet reflected in the underlying price.

Price Performance and Technical Context

Sun Pharma has been on a downward trajectory for two consecutive sessions, losing 1.46% cumulatively. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, indicating a longer-term uptrend remains intact. However, it is below its 5-day and 20-day moving averages, signalling short-term weakness and potential consolidation or correction.

Investor participation has been rising, with delivery volume on 23 March reaching 20.15 lakh shares, an 18.06% increase compared to the five-day average. This heightened delivery volume suggests genuine accumulation or distribution rather than purely speculative trading.

Market Positioning and Potential Directional Bets

The surge in open interest alongside rising volume points to increased interest from both institutional and retail traders in Sun Pharma's derivatives. The 13.37% jump in OI is significant for a large-cap pharmaceutical stock, indicating fresh positions are being established rather than existing ones being squared off.

Given the stock's recent underperformance relative to its sector and the broader market, this could imply that traders are either hedging existing long positions or speculating on a potential rebound. The fact that the stock remains above key long-term moving averages supports the latter hypothesis, suggesting that investors may be positioning for a recovery after the short-term dip.

Alternatively, the elevated options value, which dwarfs futures turnover, may indicate a preference for more nuanced strategies such as spreads or straddles, reflecting uncertainty about the stock's near-term direction but anticipation of increased volatility.

Sun Pharma's current Mojo Score of 72.0 and an upgraded Mojo Grade from Hold to Buy as of 23 February 2026 further reinforce a positive medium-term outlook. The large-cap pharmaceutical giant, with a market capitalisation of ₹4,20,267.51 crore, remains a key player in the sector, attracting sustained investor interest despite recent price softness.

Liquidity and Trading Considerations

Liquidity remains ample for sizeable trades, with the stock's average traded value supporting transaction sizes up to ₹9.61 crore based on 2% of the five-day average traded value. This ensures that institutional investors can enter or exit positions without significant market impact, which is crucial given the increased derivatives activity.

Investors should note the divergence between short-term price weakness and rising open interest, which often precedes a significant price move. Monitoring changes in the put-call ratio and strike-wise open interest could provide further clues on market sentiment and directional bias.

Outlook and Investor Takeaways

Sun Pharmaceutical Industries Ltd's recent derivatives activity highlights a market in flux, with investors recalibrating positions amid short-term price weakness but a constructive medium-term outlook. The upgraded Mojo Grade to Buy and a solid Mojo Score of 72.0 reflect confidence in the company's fundamentals and sector positioning.

Investors should watch for confirmation of directional bets through price action in the coming sessions. A sustained rebound above the 5-day and 20-day moving averages would validate the bullish positioning implied by rising open interest. Conversely, a breakdown below key support levels could trigger a reassessment of risk.

Given the stock's liquidity and active derivatives market, Sun Pharma remains a compelling candidate for both strategic long-term investors and tactical traders seeking to capitalise on volatility and directional shifts.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →